Table 3.
Predicting BARQ AUC Scores: Multivariate Analyses
| 3-day AUC | 30-day AUC | 365-day AUC | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variable | β | 95% CI | Standardized Beta | β | 95% CI | Standardized Beta | β | 95% CI | Standardized Beta | |
| Gender | Male (0) vs. Female (1) | −0.05 | −0.12, 0.02 | −0.02 | −0.05 | −0.12, 0.02 | −0.02 | – | – | – |
| SOAPP-R | Low (0) vs. High (1) | 0.14 | 0.06, 0.21 | 0.07 | 0.15 | 0.07, 0.24 | 0.08 | 0.13 | 0.04, 0.22 | 0.07 |
| Education | – | – | – | – | – | – | −0.04 | −0.09, 0.01 | −0.03 | |
| Duration of chronic pain | – | – | – | – | – | – | 0.06 | 0.005, 0.12 | 0.03 | |
| Last Pain VAS | – | – | – | 0.02 | 0.003, 0.04 | 0.04 | – | – | – | |
| PHQ-2 | Total | – | – | – | – | – | – | 0.03 | 0.00, 0.05 | 0.05 |
| ISI | Total | 0.01 | −0.001, 0.12 | 0.04 | 0.01 | 0.00, 0.01 | 0.04 | – | – | – |
| Number Pain Dx | 0.02 | 0.00, 0.04 | 0.03 | 0.01 | −0.004, 0.03 | 0.03 | – | – | – | |
| BPI (Primary Pain) | Severity | 0.02 | 0.004, 0.04 | 0.04 | – | – | – | – | – | – |
| Interference | – | – | – | – | – | – | 0.02 | 0.01, 0.04 | 0.05 | |
| BIS-11 | Attentional | −0.01 | −0.02, 0.003 | −0.03 | −0.01 | −0.02, 0.002 | −0.04 | −0.01 | −0.03, −0.001 | −0.07 |
| Motor | – | – | – | – | – | – | 0.01 | 0.00, 0.02 | 0.05 | |
| Non-planning | 0.01 | 0.00, 0.01 | 0.04 | 0.01 | 0.003, 0.02 | 0.06 | 0.01 | 0.00, 0.01 | 0.05 | |
Multivariate analysis for final model between participants at high versus low risk for opioid misuse. Abbreviations: BARQ Benefit vs. Addiction Risk Questionnaire (BARQ); Confidence Interval (CI); area under the curve (AUC); Screener and Opioid Assessment for Patients in Pain-Revised (SOAPP-R); Brief Pain Inventory (BPI); Insomnia Severity Index (ISI); Diagnosis (Dx); Barratt Impulsiveness Scale version 11 (BIS-11). p <.05. p<0.10. If “–“ appears in the column, that indicates the variable was not included in the final model.